Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

被引：5
|
作者：
Hussain, Syed A.
Maroto, Pablo
Climent, Miguel Angel
Bianchini, Diletta
Jones, Robert Hugh
Lin, Chia-Chi
Wang, Shian-Shiang
Dean, Emma
Crossley, Kate
Schlieker, Laura
Bogenrieder, Thomas
De Bono, Johann S.
机构：
[1] Univ Sheffield, Acad Unit Oncol, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Inst Canc Res, London, England
[5] Royal Marsden, London, England
[6] Velindre Canc Ctr, Cardiff, S Glam, Wales
[7] Cardiff Univ, Cardiff, S Glam, Wales
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[12] Boehringer Ingelheim Pharma Gmbh & Co KG, Staburo Gmbh & Co KG, Munich, Germany
[13] Boehringer Ingelheim RCV, Vienna, Austria
[14] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)
    Shi, Zhen
    Sweeney, Christopher
    Bracarda, Sergio
    Sternberg, Cora N.
    Chi, Kim N.
    Olmos, David
    Sandhu, Shahneen Kaur
    Massard, Christophe
    Matsubara, Nobuaki
    Harle-Yge, Marie-Laurence
    Nowicka, Malgorzata
    Wongchenko, Matthew
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010
    Yu, Evan Y.
    Park, Se Hoon
    Huang, Yi-Hsiu
    Bennamoun, Mostefa
    Xu, Lu
    Kim, Jeri
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [43] BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm)
    Hussain, Maha H. A.
    Kocherginsky, Masha
    Agarwal, Neeraj
    Adra, Nabil
    Zhang, Jingsong
    Paller, Channing Judith
    Picus, Joel
    Reichert, Zachery R.
    Szmulewitz, Russell Zelig
    Tagawa, Scott T.
    Kuzel, Timothy
    Bazzi, Latifa
    Daignault-Newton, Stephanie
    Whang, Young E.
    Dreicer, Robert
    Stephenson, Ryan D.
    Rettig, Matthew
    Shevrin, Daniel
    Chinnaiyan, Arul
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 19 - 19
  • [44] Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Severi, Stefano
    Gori, Stefania
    Galli, Luca
    Aieta, Michele
    Facchini, Gaetano
    Masini, Cristina
    Gasparro, Donatello
    Fratino, Lucia
    Baier, Susanne
    Scarpi, Emanuela
    Testoni, Sara
    Sirna, Valeria
    Valmorri, Linda
    Vertogen, Bernadette
    Paganelli, Giovanni
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [45] Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.
    Thiery-Vuillemin, Antoine
    Saad, Fred
    Armstrong, Andrew J.
    Oya, Mototsugu
    Vianna, Karina Costa Maia
    Ozguroglu, Mustafa
    Gedye, Craig
    Buchschacher, Gary L.
    Lee, Ji Youl
    Emmenegger, Urban
    Navratil, Jiri
    Virizuela, Juan Antonio
    Salazar, Anibal
    Maillet, Denis
    Uemura, Hiroji
    Kim, Jeri
    Lukacs, Edit
    Barker, Laura
    Degboe, Arnold N.
    Clarke, Noel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC).
    Crabb, Simon J.
    Griffiths, Gareth Owen
    Marwood, Ellice
    Dunkley, Denise
    Downs, Nichola
    Martin, Karen
    Light, Michelle
    Northey, Josh
    Whitehead, Amy
    Shaw, Emily C.
    Birtle, Alison Jane
    Bahl, Amit
    Elliott, Tony
    Westbury, Charlotte
    Sundar, Santhanam
    Robinson, Angus
    Jagdev, Satinder
    Kumar, Satish
    Khoo, Vincent
    Jones, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.
    Khalaf, Daniel J.
    Sunderland, Katherine
    Eigl, Bernhard J.
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Kollmannsberger, Christian K.
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA).
    Chi, Kim N.
    Sweeney, Christopher
    Jacobs, Cindy
    Stewart, Patricia S.
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Vaishampayan, Ulka N.
    Keessen, Marianne
    Heath, Elisabeth I.
    Dreicer, Robert
    Buchler, Tomas
    Arkosy, Peter Ferenc
    Csoszi, Tibor
    Wiechno, Pawel J.
    Kholtobin, Denis
    Kopyltsov, Evgeny
    Shore, Neal D.
    Nosov, Aleander
    Orlov, Sergey
    Plekhanov, Alexey
    Smagina, Maria
    Varlamov, Sergey
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Hauke, Ralph J.
    Call, Justin A.
    Sun, Jichao
    Casey, Denise
    Wei, Xiao X.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS242 - TPS242
12345